Bevacizumab used in ocular disease exerts its therapeutic effect by inhibiting what?

Prepare for the PANCE Board Exam with our comprehensive quiz. Study with detailed questions and explanations. Sharpen your skills and boost your confidence for exam day!

Multiple Choice

Bevacizumab used in ocular disease exerts its therapeutic effect by inhibiting what?

Explanation:
In ocular disease, abnormal blood vessel growth and leakage are driven by vascular endothelial growth factor, or VEGF. Bevacizumab is a monoclonal antibody that binds VEGF, preventing it from activating its receptors on retinal and choroidal vessels. This halts new vessel formation and reduces vascular permeability, which helps lessen edema and neovascularization that threaten vision. The other molecules listed—COX-2, IL-6, and TGF-beta—are involved in different pathways (inflammation, fibrosis, or other signaling) and are not targets of bevacizumab.

In ocular disease, abnormal blood vessel growth and leakage are driven by vascular endothelial growth factor, or VEGF. Bevacizumab is a monoclonal antibody that binds VEGF, preventing it from activating its receptors on retinal and choroidal vessels. This halts new vessel formation and reduces vascular permeability, which helps lessen edema and neovascularization that threaten vision. The other molecules listed—COX-2, IL-6, and TGF-beta—are involved in different pathways (inflammation, fibrosis, or other signaling) and are not targets of bevacizumab.

More practice questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy